JP2022550698A - 組織を修復または増加させるための組成物および方法 - Google Patents
組織を修復または増加させるための組成物および方法 Download PDFInfo
- Publication number
- JP2022550698A JP2022550698A JP2022517352A JP2022517352A JP2022550698A JP 2022550698 A JP2022550698 A JP 2022550698A JP 2022517352 A JP2022517352 A JP 2022517352A JP 2022517352 A JP2022517352 A JP 2022517352A JP 2022550698 A JP2022550698 A JP 2022550698A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- peg
- molecular weight
- oxygen carrier
- cellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims description 35
- 230000003190 augmentative effect Effects 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 59
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 40
- 229920000642 polymer Polymers 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 230000010412 perfusion Effects 0.000 claims abstract description 12
- 230000001965 increasing effect Effects 0.000 claims abstract description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 47
- 229910052760 oxygen Inorganic materials 0.000 claims description 47
- 239000001301 oxygen Substances 0.000 claims description 47
- 210000004369 blood Anatomy 0.000 claims description 41
- 239000008280 blood Substances 0.000 claims description 41
- 230000001413 cellular effect Effects 0.000 claims description 23
- 210000003743 erythrocyte Anatomy 0.000 claims description 21
- 238000001802 infusion Methods 0.000 claims description 13
- 238000001990 intravenous administration Methods 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 235000002639 sodium chloride Nutrition 0.000 claims description 7
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 102000001554 Hemoglobins Human genes 0.000 claims description 4
- 108010054147 Hemoglobins Proteins 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 235000011148 calcium chloride Nutrition 0.000 claims description 4
- 230000001269 cardiogenic effect Effects 0.000 claims description 4
- 206010007625 cardiogenic shock Diseases 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 235000011147 magnesium chloride Nutrition 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 239000001540 sodium lactate Substances 0.000 claims description 4
- 235000011088 sodium lactate Nutrition 0.000 claims description 4
- 229940005581 sodium lactate Drugs 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 48
- 230000035939 shock Effects 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 11
- 229940001447 lactate Drugs 0.000 description 11
- 230000002503 metabolic effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 208000014674 injury Diseases 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 230000008733 trauma Effects 0.000 description 8
- 230000003204 osmotic effect Effects 0.000 description 7
- 238000004062 sedimentation Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 239000010836 blood and blood product Substances 0.000 description 6
- 229940125691 blood product Drugs 0.000 description 6
- 230000004089 microcirculation Effects 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 206010009192 Circulatory collapse Diseases 0.000 description 3
- 208000028399 Critical Illness Diseases 0.000 description 3
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 3
- 206010039238 Rouleaux formation Diseases 0.000 description 3
- 206010049771 Shock haemorrhagic Diseases 0.000 description 3
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000011808 rodent model Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002637 fluid replacement therapy Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000032026 No-Reflow Phenomenon Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000005393 Sodium-Potassium-Exchanging ATPase Human genes 0.000 description 1
- 108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004706 cardiovascular dysfunction Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 206010010121 compartment syndrome Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229940053703 hextend Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明は、陸軍(MRMC)によって付与された認可番号W81XWH-16-2-0040の下で政府支援を用いて開発したものである。政府は本発明において一定の権利を有する。
本発明は、概して、虚血組織における微小循環への酸素送達を回復または増加させるのに有用な、高分子量および低分子量のポリマーを含む組成物に関する。
出血性ショック蘇生のためのPEGポリマーのサイズ
致死性出血性ショックおよび低容量蘇生(LVR)の着実な齧歯類モデルにおける初期の研究は、典型的な不透過性分子が非常に有効であったことを示し、ショックに対する耐性の指標となる低容量蘇生(LVR)時間を2倍にした。他の心血管および代謝の結果も、生理食塩水容量コントロール群に対して2倍に改善された。効果を最適化するために、本発明者らは、浸透圧反射係数が1未満(毛細血管空間内に留まるアルブミンのような純粋な膨張剤)、かつ、0より大きい(毛細血管と間隙空間との間で自由に平衡化するグルコン酸のような純粋な非透過剤)である不透過性分子を探索した。本発明者らは、10kより大きいが100k未満のPEGポリマーが魅力的な候補であることを見出した。ショック状態におけるサイジング研究を行い、結果を酸素負債の指標としてLVR時間、蘇生後の動脈圧、および、蘇生後の血漿乳酸蓄積にて示す。これらの研究を図3に要約する。
出血性ショック蘇生のためのPEG投与量
ショック蘇生のために推奨される現在の投与量は、推定血液容積の10%に等しい体積または6.8ml/kgの単一の低容量IVボーラス注入である。使用される溶液は、ポリエチレングリコール20,000(PEG-20k)の10重量%溶液である。投与量は、注入器により5分かけて投与されるか、または静脈アクセスラインへの重力供給によって投与される。この特定の投与量は、前臨床ブタモデルと相関することが示された致死ショックの周知の齧歯類モデルにおける反復実験から試験的に決定された。これらの投与量応答データを図4に示す。これらのデータは、LVR時間および最終血漿乳酸値の結果の両方に基づいて、PEG-20k IV溶液の最適な投与量を示す。具体的には、最も効果的な蘇生結果は、最も長いLVR時間と最も低いの乳酸値を有するものである(各バーの下にmM/Lで示される)。この試験モデルにおけるこれらの基準を用いて、推定血液量(6.8ml/kg)の10%の体積投与量でPEG-20kの10%溶液としてのPEG-20k投与は、最も明らかに最適結果を示した。
配合最適化:ESR効果
激しいショック後に蘇生する際にこれらの有益な効果を有する高分子量のPEGも、全血と混合した際には赤血球沈降速度(ESR)を飛躍的に増大させる。ポリエチレングリコールポリマーは、生物学的および非生物学的物質に非特異的に結合することができる。さらに、4nMを超える分子半径を有するポリマーは、赤血球のような細胞に結合し、架橋することができ、一方で4nm未満のポリマーは結合しない。これは10-20kDaの間の分子量カットオフとして説明され、PEG-20kはRBCと相互作用するのに十分な大きさであり、大きさがPEG-10kよりも小さいと十分ではない。ショック状態の前臨床モデルにおいて、インビボで10%PEG-20k IV溶液を用いて作用させた最初の観察結果のうちの一つは、1回のPEG-20kの静脈内投与後に採取された全血サンプル中においてRBCを迅速に沈降させる能力を示した(図5-右側は、PEG-20kの10%溶液を含む。この画像は、10分後の赤血球沈降の程度を示す)。この効果を、ex vivoヒト血液中の古典的ウエスタンESR定量法を用いてPEG-20k ESR効果を定量した。通常の血液中での60分での沈降は、約2~6mmである。血液を10%PEG-20kで1:9希釈にて希釈したときに60mmに増加し、これはショック時のLVR後の希釈をシミュレートする。
Claims (34)
- 5~20%w/v濃度の分子量18,000~100,000Daを有するポリエチレングリコールポリマー(PEG);
1~30重量%濃度の分子量が1,000~10,00DaであるPEG;および
水を含む組成物であって、
前記分子量18,000~100,000Daを有するPEGと前記分子量が1,000~10,000Daを有するPEGとが、前記水中に溶解または分散している、組成物。 - 前記組成物の全体積が100~1000mlである、請求項1に記載の組成物。
- 全体積が136~680mlの範囲である、請求項2に記載の組成物。
- 前記分子量18,000~100,000Daを有するPEGが分子量20,000Daを有するPEGである、請求項1に記載の組成物。
- 前記分子量20,000Daを有するPEGが10%w/vの濃度である、請求項4に記載の組成物。
- 前記水が脱イオン水である、請求項1に記載の組成物。
- 前記組成物が、塩化ナトリウム、乳酸ナトリウム、塩化カリウム、塩化カルシウムおよび、塩化マグネシウムの1種以上をさらに含む、請求項1に記載の組成物。
- 流体を静脈内に送達するように構成されたバッグと、前記バック内の組成物とを含む静脈内注入製品であって、前記組成物が、
5~20%w/v濃度の分子量18,000~100,000Daを有するポリエチレングリコールポリマー(PEG)と;
1~20%w/v濃度の分子量1,000~10,000Daを有するPEGと;
水とを含み、
前記分子量18,000~100,000Daを有するPEGと前記分子量1,000~10,000Da
を有するPEGとが前記水中に溶解または分散している、静脈内注入製品。 - 前記組成物の全体積が100~1000mlである、請求項8に記載の静脈内注入製品。
- 総全容積が136~680mlの範囲である、請求項9に記載の静脈内注入製品。
- 前記分子量18,000~35,000Daを有するPEGが分子量20,000Daを有するPEGである、請求項8に記載の静脈内注入製品。
- 分子量20,000Daを有するPEGが10%w/vの濃度である、請求項11に記載の静脈内注入製品。
- 前記水が脱イオン水である、請求項8に記載の静脈内注入製品。
- 前記組成物が、塩化ナトリウム、乳酸ナトリウム、塩化カリウム、塩化カルシウム及び塩化マグネシウムの1種以上をさらに含む、請求項8に記載の静脈内注入製品。
- 必要とされる対象における局所的または広範囲に組織灌流を回復または増加させる方法であって、
請求項1に記載の組成物の治療上有効な量を前記対象に投与することを含む、方法。 - 前記組成物を静脈内に投与する、請求項15に記載の方法。
- 前記組成物の量が100~1000mlである、請求項15に記載の方法。
- 組成物の量が136-680mlである、請求項15に記載の方法。
- 前記対象が心原性または非心原性ショックにより広範囲にまたは局所的に組織灌流が減少している、請求項15に記載の方法。
- 細胞または無細胞酸素キャリア溶液を同時にまたは連続的に投与する工程をさらに含む、請求項15に記載の方法。
- 前記無細胞酸素キャリア溶液がヘモグロビンベースの酸素キャリア(HBOC)である、請求項20に記載の方法。
- 前記細胞性酸素キャリア溶液が全血または濃厚赤血球である、請求項20に記載の方法。
- 投与する前記細胞酸素キャリア溶液の量が組成物の非存在下で必要とされる推定血液量の50%以下である、請求項20に記載の方法。
- 前記細胞または無細胞酸素キャリア溶液を前記組成物の投与の12時間以内に投与する、請求項20に記載の方法。
- 必要とされる対象における心臓の蘇生方法であって、
請求項1に記載の組成物の治療上有効な量を前記対象に投与することを含む、方法。 - 前記組成物を静脈内に投与する、請求項25に記載の方法。
- 前記組成物の量が100~1000mlである、請求項25に記載の方法。
- 前記組成物の量が136~680mlの範囲である、請求項25に記載の方法。
- 前記対象が心原性または非心原性ショックを受ける、請求項25に記載の方法。
- 細胞または無細胞酸素キャリア溶液を同時にまたは連続的に投与する工程をさらに含む、請求項25に記載の方法。
- 前記無細胞酸素キャリア溶液がヘモグロビンベースの酸素キャリア(HBOC)である、請求項30に記載の方法。
- 前記細胞酸素キャリア溶液が全血または濃厚赤血球である、請求項30に記載の方法。
- 投与する前記細胞酸素キャリア溶液の量が組成物の非存在下で必要とされる推定血液量の50%以下である、請求項30に記載の方法。
- 前記細胞または無細胞酸素キャリア溶液を前記組成物の投与の12時間以内に投与する、請求項30に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962907066P | 2019-09-27 | 2019-09-27 | |
US62/907,066 | 2019-09-27 | ||
PCT/US2020/025103 WO2020205459A1 (en) | 2019-03-29 | 2020-03-27 | Polymer agents for cardiopulmonary resuscitation |
USPCT/US2020/025103 | 2020-03-27 | ||
PCT/US2020/052075 WO2021061687A1 (en) | 2019-09-27 | 2020-09-23 | Compositions and methods for restoring or increasing tissue perfusion |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022550698A true JP2022550698A (ja) | 2022-12-05 |
JPWO2021061687A5 JPWO2021061687A5 (ja) | 2024-04-23 |
Family
ID=75166407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022517352A Pending JP2022550698A (ja) | 2019-09-27 | 2020-09-23 | 組織を修復または増加させるための組成物および方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220387478A1 (ja) |
EP (1) | EP4034134A4 (ja) |
JP (1) | JP2022550698A (ja) |
KR (1) | KR20220071213A (ja) |
CN (1) | CN114786684A (ja) |
AU (1) | AU2020354996B2 (ja) |
CA (1) | CA3151433C (ja) |
IL (1) | IL291578B2 (ja) |
WO (1) | WO2021061687A1 (ja) |
ZA (1) | ZA202203972B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023091642A1 (en) * | 2021-11-18 | 2023-05-25 | Virginia Commonwealth University | Modular field-stable bio-artificial blood substitute |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999008514A1 (en) * | 1997-08-20 | 1999-02-25 | Lxr Biotechnology, Inc. | Compositions containing polyethylene glycol and uses thereof |
EP1389121B1 (en) * | 2001-04-24 | 2012-02-22 | Purdue Research Foundation | Method and compositions for treating mammalian nerve tissue injuries |
GB0720716D0 (en) * | 2007-10-23 | 2007-12-05 | York Pharma Plc | Novel formulation |
CN105362221A (zh) * | 2009-03-03 | 2016-03-02 | 爱尔康研究有限公司 | 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 |
US9399027B2 (en) * | 2011-09-08 | 2016-07-26 | Virginia Commonwealth University | Organ protection solution and its method of use |
US10307398B2 (en) * | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
-
2020
- 2020-09-23 EP EP20869487.7A patent/EP4034134A4/en active Pending
- 2020-09-23 US US17/761,792 patent/US20220387478A1/en active Pending
- 2020-09-23 CA CA3151433A patent/CA3151433C/en active Active
- 2020-09-23 JP JP2022517352A patent/JP2022550698A/ja active Pending
- 2020-09-23 KR KR1020227012487A patent/KR20220071213A/ko unknown
- 2020-09-23 CN CN202080076184.3A patent/CN114786684A/zh active Pending
- 2020-09-23 WO PCT/US2020/052075 patent/WO2021061687A1/en active Application Filing
- 2020-09-23 AU AU2020354996A patent/AU2020354996B2/en active Active
- 2020-09-23 IL IL291578A patent/IL291578B2/en unknown
-
2022
- 2022-04-07 ZA ZA2022/03972A patent/ZA202203972B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220071213A (ko) | 2022-05-31 |
US20220387478A1 (en) | 2022-12-08 |
IL291578B2 (en) | 2023-03-01 |
CN114786684A (zh) | 2022-07-22 |
CA3151433A1 (en) | 2021-04-01 |
ZA202203972B (en) | 2023-12-20 |
IL291578A (en) | 2022-05-01 |
AU2020354996B2 (en) | 2022-12-01 |
AU2020354996A1 (en) | 2022-04-07 |
IL291578B (en) | 2022-11-01 |
CA3151433C (en) | 2023-05-16 |
EP4034134A4 (en) | 2023-10-18 |
WO2021061687A1 (en) | 2021-04-01 |
EP4034134A1 (en) | 2022-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ho et al. | Effects of storage on efficacy of red cell transfusion: when is it not safe? | |
US8409126B2 (en) | Selective cytopheresis devices and related methods thereof | |
Pearl et al. | Leukocyte-depleted reperfusion of transplanted human hearts prevents ultrastructural evidence of reperfusion injury | |
US9399027B2 (en) | Organ protection solution and its method of use | |
Czer et al. | Survival and allograft rejection rates after combined heart and kidney transplantation in comparison with heart transplantation alone | |
AU2012364760B2 (en) | Cartridge and method for increasing myocardial function | |
Faithfull | Fluorocarbons: Current status and future applications | |
Harrington et al. | Pre-clinical studies using OxyVita hemoglobin, a zero-linked polymeric hemoglobin: a review | |
JP2022550698A (ja) | 組織を修復または増加させるための組成物および方法 | |
US11007227B2 (en) | Compositions and methods for restoring or increasing tissue perfusion | |
US8753806B2 (en) | Organ protection solution and method of use | |
Bragin et al. | Addition of drag-reducing polymers to colloid resuscitation fluid enhances cerebral microcirculation and tissue oxygenation after traumatic brain injury complicated by hemorrhagic shock | |
Burns et al. | Blood-brain barrier: morphology, physiology, and effects of contrast media | |
Van Hoogmoed et al. | In vitro evaluation of an intraluminal solution to attenuate effects of ischemia and reperfusion in the small intestine of horses | |
US20240049700A1 (en) | Lipid layer preservation | |
Krzych et al. | Does fluid resuscitation with balanced solutions induce electrolyte and metabolic abnormalities? An in vitro assessment | |
US10278988B2 (en) | Reducing the proliferation of carcinoma cells by administration of a poly-oxygenated metal hydroxide | |
Kameneva et al. | Denis E. Bragin, Olga A. Bragina, Lucy Berliba | |
Diethelm et al. | Preservation of cadaver kidneys using hypothermig, hyperosmolar, intracellular washout solution | |
Scott et al. | Preservation of cadaver kidneys before transplantation | |
López-Hernández et al. | VERAPAMIL-LIDOCAINE DONOR DECREASES ACUTE TUBULAR NECROSIS, IN CADAVERIC KIDNEY TRANSPLANTATION: 1837 | |
Fonouni et al. | INFLUENCE OF A MODIFIED PRESERVATION SOLUTION IN PROLONGING THE COLD ISCHEMIC PERIOD–A COMPARATIVE STUDY IN A PORCINE MODEL OF ALLOGRAFT KIDNEY TRANSPLANTATION: 1840 | |
Severs et al. | Full Review A critical appraisal of intravenous fluids: from the physiological basis to clinical evidence | |
Wilson et al. | Perflubron Emulsion Does Not Cause Neutrophil (PMN) Activation In-Vivo. | |
WO2015160692A1 (en) | Organ protection solution and method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220408 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230619 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240412 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240515 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240520 |